Search
ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
- blonca9
- Dec 8, 2024
- 1 min read
The data showed a 62% CR/sCR at a median follow-up of 9.5 months. He discusses the patient population, next steps, and the work that partner Kite is doing in an earlier line setting.